Bookmark

Add to MyYahoo RSS

Bristol Myers Squibb News

News on Bristol Myers Squibb (Ticker: BMY) continually updated from thousands of sources around the net.

5 hrs ago | AmericanBankingNews.com

Bristol-Myers Squibb Research Coverage Started at Deutsche Bank

In other Bristol-Myers Squibb news, SVP Autenried Paul Von sold 20,000 shares of the stock on the open market in a transaction dated Tuesday, August 19th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bristol Myers Squibb, Bristol-Myers Squibb, Bloomsbury Publishing, Media, Publishing, Medarex, Pharmaceuticals

9 hrs ago | TheStreet.com

Will This Coverage Initiation Affect Bristol-Myers Squibb (BMY) Stock Today?

Separately, TheStreet Ratings team rates BRISTOL-MYERS SQUIBB CO as a "buy" with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation: "We rate BRISTOL-MYERS SQUIBB CO a BUY.

Comment?

Related Topix: TheStreet, Biotech, Medicine, Healthcare Industry

13 hrs ago | Information Technology

European Commission Approves Bristol-Myers Squibb's Daklinza...

Bristol-Myers Squibb Company i 1 2 today announced that the European Commission has approved Daklinza , a potent, pan-genotypic NS5A replication complex inhibitor , for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex, Hepatitis, Health, Marketing, World News, Germany

17 hrs ago | TheStreet.com

Analysts' Actions: Akamai, Bristol-Myers, Eli Lilly, Merck, Pfizer

Twelve-month price target is $71. Company is an industry leader that can benefit from multiple secular trends, Robert Baird said.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Eli Lilly

17 hrs ago | TheStreet.com

Analysts' Actions: Akamai, Bristol-Myers, Eli Lilly, Merck, Pfizer

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Eli Lilly, Mozilla, TheStreet

21 hrs ago | Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Corp., le principal fabricant de blocs d'alimentation portables et geant technologique a l'origine des marques Energizer , SpareOneTM et PowerSkin la... )--Research and Markets has announced the addition of the "ICT investment trends in Germany - Enterprise ICT... )--Regulatory News: Trelleborg Charlotta Grahs has been appointed as the new General ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex, Televisions

Mon Aug 25, 2014

Reuters

Exclusive: U.S. approval of Merck cancer immunotherapy expected soon

U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

Comment?

Related Topix: Biotech, Merck , Medicine, Healthcare Industry, Oncology, Merck & Co., Food and Drug Administration, Skin Cancer, Health

Fri Aug 22, 2014

The Motley Fool

3 Reasons Bristol-Myers Squibb's Stock Could Rise

The patent cliff has forced most Big Pharmas to make major transformations in their businesses over the past few years.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bloomsbury Publishing, Bristol Myers Squibb, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals, Amylin Pharmaceuticals

Thu Aug 21, 2014

Customer Interaction Solutions

U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein...

U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism , and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy Bristol-Myers Squibb Company and Pfizer Inc. today announced the U.S. Food and Drug Administration has approved a Supplemental New Drug Application for Eliquis for the ... (more)

Comment?

Related Topix: Healthcare Law, Food and Drug Administration, Law, Biotech, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex, Pfizer

Reuters

FDA OKs use of Eliquis to treat leg, lung clots

Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat dangerous blood clots in the legs and lungs.

Comment?

Related Topix: Food and Drug Administration, Biotech, Medicine, Healthcare Industry

Wed Aug 20, 2014

Biopharm

Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen

Bristol-Myers Squibb and Celgene have established a clinical-trial collaboration to evaluate the safety, tolerability, and preliminary efficacy of a combination regimen of Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, OPDIVO , and Celgene's nab technology-based chemotherapy ABRAXANE , in a Phase I study.

Comment?

Related Topix: Bloomsbury Publishing, Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Bristol-Myers Squibb, Pharmaceuticals, Healthcare Industry, Cancer, Health

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Superfish is the #1 ranked software... )--CTRL was formed to create a forum where an open source philosophy is used to incorporate the best ideas in the practice of law through a range of technological innov... )--The AcroMetrix Oncology Hotspot Control provides a quality control material that can be used in laboratories with different NGS ... (more)

Comment?

Related Topix: Semiconductors, Vishay Intertechnology, Electronics, Biotech, Medicine, Healthcare Industry, Pfizer, Energy, AES, Retail, Target

Tue Aug 19, 2014

AmericanBankingNews.com

Bristol-Myers Squibb SVP Sells $997,800 in Stock

Bristol-Myers Squibb SVP Autenried Paul Von unloaded 20,000 shares of the company's stock on the open market in a transaction dated Tuesday, August 19th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex

Mon Aug 18, 2014

Business Journal

Bristol-Myers Squibb targets major block of space in East Cambridge

Bristol-Myers Squibb is vetting several property options in East Cambridge, increasingly the office and lab market of choice for many of the largest life sciences companies in the world.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bloomsbury Publishing, Bristol Myers Squibb, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals, Waltham, MA

BayStreet.ca

Premier Biotechnology & Anti-CTLA4

Whitefish, MT / August 18, 2014 / Many forms of cancer are characterized by a lack of cellular apoptosis and down-regulation of the immune system.

Comment?

Related Topix: Whitefish, MT, Bloomsbury Publishing, Biotech, Publishing, Media, Medarex, Medicine, Healthcare Industry, Food and Drug Administration

Wed Aug 13, 2014

Sys-Con Media

The Impact of Genericization in the Unipolar Depression Market Will...

By 2023, total major-market sales for unipolar depression will reach under Later-line treatments: Newer antidepressant therapies will be prescribed as third- and fourth-line treatment for patients whose depressive symptoms are inadequately addressed by generic selective serotonin reuptake inhibitors and/or serotonin and norepinephrine reuptake ... (more)

Comment?

Related Topix: Depression, Health, Cymbalta, Duloxetine (generic), Biotech, Medicine, Healthcare Industry

Tue Aug 12, 2014

Seeking Alpha

Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies

Tumor cells that refuse to die have led researchers to develop immuno-oncology drugs, a brand new class, with Big Pharma participation.

Comment?

Related Topix: Oncology, Medicine, Biotech, Healthcare Industry, Medarex, Dendreon, Merck , Merck & Co.

Mon Aug 11, 2014

Benzinga

Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments

U.S. markets managed to squeeze out small gains in lighter than normal volume as geopolitical tensions may be calming down.

Comment?

Related Topix: Investment Banking, Jefferies Group, Investment Services, Financial Services, Biotech, Bloomsbury Publishing, Media, Publishing, Medarex, Medicine, Healthcare Industry, Banking, Citigroup, CitiMortgage

AmericanBankingNews.com

Bristol-Myers Squibb Price Target Raised to $45.00 at Jefferies Group

The firm currently has a "hold" rating on the stock. Jefferies Group's price target suggests a potential downside of 8.52% from the company's current price.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex, Investment Banking, Financial Services, Jefferies Group, Investment Services

Fri Aug 08, 2014

BayStreet.ca

Small companies lead the I-O class of Cancer Therapies

Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Oncology, Medarex, Dendreon, Merck , Merck & Co.

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••